Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms | Zendy

Martín E. Stryjewski | Zendy; Donald R. Graham | Zendy; Samuel E. Wilson | Zendy; William O’Riordan | Zendy; David M. Young | Zendy; Arnold Lentnek | Zendy; Douglas P. Ross | Zendy; Vance G. Fowler | Zendy; Alan R. Hopkins | Zendy; H. David Friedland | Zendy; Steven L. Barriere | Zendy; Michael M. Kitt | Zendy; G. Ralph Corey | Zendy

Open Access

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

Author(s) -

Martín E. Stryjewski,

Donald R. Graham,

Samuel E. Wilson,

William O’Riordan,

David M. Young,

Arnold Lentnek,

Douglas P. Ross,

Vance G. Fowler,

Alan R. Hopkins,

H. David Friedland,

Steven L. Barriere,

Michael M. Kitt,

G. Ralph Corey

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/587896

Subject(s) - medicine , vancomycin , confidence interval , methicillin resistant staphylococcus aureus , adverse effect , surgery , antibiotics , staphylococcus aureus , population , gastroenterology , microbiology and biotechnology , environmental health , biology , bacteria , genetics

Telavancin is an investigational, rapidly bactericidal lipoglycopeptide with a multifunctional mechanism of action.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research